ARTICLE | Company News
Metris licenses a JNJ compound
August 7, 2002 7:00 AM UTC
Metris (Wokingham, U.K.) received an exclusive worldwide license to an undisclosed preclinical oncology compound from Johnson & Johnson (JNJ). Metris, which develops treatments for gynecological condi...